Results 171 to 180 of about 7,732 (197)

A comprehensive analysis of immune checkpoint receptor-ligand pairs in aortic diseases highlights the immunosuppressive roles of CD155 and CD274. [PDF]

Genes Dis
Shao Y, Saaoud F, Xu K, Lu Y, Wu S, Martinez L, Vazquez-Padron R, Kosmider B, Wang H, Yang X.   +9 more
europepmc   +1 more source

The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy. [PDF]

J Exp Clin Cancer Res
Hussein OJ, Rayan M, Matarid TR, Elkhalifa D, Abunada HH, Therachiyil L, Khalil A, Uddin S, Maccalli C, Korashy HM.   +9 more
europepmc   +1 more source

The co-inhibitory receptor TIGIT promotes tissue-protective functions in T cells. [PDF]

Nat Immunol
Panetti C, Daetwyler R, Moncsek A, Patikas N, Agrafiotis A, Tang A, Andreata F, Fumagalli V, De Lima J, Wen L, King CG, Vasanthakumar A, Iannacone M, Kallies A, Yermanos A, Hemberg M, Joller N.   +16 more
europepmc   +1 more source

NK cells in HPV-related tumorigenesis: mechanisms and clinical applications. [PDF]

Front Cell Infect Microbiol
Deng J, Liu Y, Ma X, Li D, Li Z, Pan Y, Zeng X.   +6 more
europepmc   +1 more source

Increased Soluble CD155 in the Serum of Cancer Patients

Increased Soluble CD155 in the Serum of Cancer Patients
openaire  

Some of the next articles are maybe not open access.

Related searches:

CD155: A Key Receptor Playing Diversified Roles

Current Molecular Medicine, 2022
: Cluster of differentiation (CD155), formerly identified as poliovirus receptor (PVR) and later as immunoglobulin molecule, is involved in cell adhesion, proliferation, invasion and migration. It is a surface protein expressed mostly on normal and transformed malignant cells. The expression of the receptor varies based on the origin of tissue.
Shyam Sundar, Nandi, Trupti, Gohil, Sonali Ankush, Sawant, Upendra Pradeep, Lambe, Sudip, Ghosh, Snehasis, Jana   +5 more
openaire   +2 more sources

CD155 in tumor progression and targeted therapy

Cancer Letters, 2022
CD155, also known as the poliovirus receptor (PVR), has received considerable attention in recent years because of its intrinsic and extrinsic roles in tumor progression. Although barely expressed in host cells, CD155 is upregulated in tumor-infiltrating myeloid cells.
Zhan, Meixiao, Zhang, Zhiren, Zhao, Xiaoguang, Zhang, Yuncong, Liu, Tianqing (Michelle) (R20191), Lu, Ligong, Li, Xianyang   +6 more
openaire   +3 more sources

CD155 is a putative therapeutic target in medulloblastoma

Clinical and Translational Oncology, 2022
Medulloblastoma is the most common pediatric malignant brain tumor, consisting of four molecular subgroups (WNT, SHH, Group 3, Group 4) and 12 subtypes. Expression of the cell surface poliovirus receptor (PVR), CD155, is necessary for entry of the viral immunotherapeutic agent, PVSRIPO, a polio:rhinovirus chimera.
Sean Li, Roger McLendon, Eric Sankey, Reb Kornahrens, Anne-Marie Lyne, Florence Marie Géraldine Cavalli, Zachary McKay, James Emmett Herndon, Marc Remke, Daniel Picard, Matthias Gromeier, Michael Brown, Eric Michael Thompson   +12 more
openaire   +2 more sources

Tumor intrinsic and extrinsic immune functions of CD155

Seminars in Cancer Biology, 2020
CD155 (PVR/necl5/Tage4), a member of the nectin-like family of adhesion molecules, is highly upregulated on tumor cells across multiple cancer types and has been associated with worse patient outcomes. In addition to well described cell-intrinsic roles promoting tumor progression and metastasis, CD155 has now been implicated in immune regulation.
O'Donnell, Jake. S., Madore, Jason, Li, Xian-Yang, Smyth, Mark J.   +3 more
openaire   +3 more sources